Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 8:12:853246.
doi: 10.3389/fonc.2022.853246. eCollection 2022.

Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel

Palak Kundu  1 , Eric Y Lin  1   2 , Stephanie M Yoon  1 , Neil R Parikh  1 , Dan Ruan  1 , Amar U Kishan  1 , Alan Lee  1 , Michael L Steinberg  1 , Albert J Chang  1
Affiliations

Rectal Radiation Dose and Clinical Outcomes in Prostate Cancer Patients Treated With Stereotactic Body Radiation Therapy With and Without Hydrogel

Palak Kundu et al. Front Oncol. .

Abstract

Background: Patients with prostate cancer treated with stereotactic body radiation therapy (SBRT) may experience gastrointestinal (GI) toxicity. The hydrogel may mitigate this toxicity by reducing the rectal radiation dose. The purpose of this study is to compare rectal radiation dose and GI toxicity in patients receiving prostate SBRT with and without hydrogel.

Methods: Consecutive patients treated with SBRT between February 2017 and January 2020 with and without hydrogel were retrospectively identified. Baseline characteristics including prostate volume, rectal diameter, body mass index (BMI), age, pretreatment prostate-specific antigen (PSA), Gleason score, T-stage, and androgen deprivation therapy (ADT) usage were compared. Dosimetric outcomes (V40Gy, V36Gy, V32Gy, V38Gy, and V20Gy), rates of acute (≤90 days) and late (>90 days) GI toxicity, and PSA outcomes were evaluated for patients with and without hydrogel.

Results: A total of 92 patients were identified (51 hydrogel and 41 non-hydrogel). There were no significant differences in baseline characteristics. Rectal V38(cc) was significantly less in the hydrogel group (mean 0.44 vs. mean 1.41 cc, p = 0.0002), and the proportion of patients with V38(cc) < 2 cc was greater in the hydrogel group (92% vs. 72%, p = 0.01). Rectal dose was significantly lower for all institutional dose constraints in the hydrogel group (p < 0.001). The hydrogel group experienced significantly less acute overall GI toxicity (16% hydrogel vs. 28% non-hydrogel, p = 0.006), while the difference in late GI toxicity trended lower with hydrogel but was not statistically significant (4% hydrogel vs. 10% non-hydrogel, p = 0.219). At a median follow-up of 14.8 months, there were no biochemical recurrences in either group.

Conclusion: Hydrogel reduces rectal radiation dose in patients receiving prostate SBRT and is associated with a decreased rate of acute GI toxicity.

Keywords: SBRT (stereotactic body radiation therapy); hydrogel; outcomes; prostate cancer; radiation oncology.

PubMed Disclaimer

Conflict of interest statement

AC received consulting fees and lecture payments from Boston Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The hydrogel pushes the rectum out of high-dose radiation field.
Figure 2
Figure 2
Radiation dose parameters in the hydrogel and non-hydrogel cohorts. Error bars show standard error. “***” denotes p < 0.001.
See this image and copyright information in PMC

References

    1. Malouff TD, Stross WC, Seneviratne DS, Waddle MR, May BC, Buskirk SJ, et al. . Current Use of Stereotactic Body Radiation Therapy for Low and Intermediate Risk Prostate Cancer: A National Cancer Database Analysis. Prostate Cancer Prostatic Dis (2020) 23:349–55. doi: 10.1038/s41391-019-0191-9 - DOI - PubMed
    1. NCCN Guidelines (2021). Available at: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (Accessed 30 June 2021).
    1. Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, et al. . Ultra-Hypofractionated Versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, non-Inferiority, Phase 3 Trial. Lancet (2019) 394(10196):385–95. doi: 10.1016/S0140-6736(19)31131-6 - DOI - PubMed
    1. Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, et al. . Intensity-Modulated Fractionated Radiotherapy Versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Findings From an International, Randomised, Open-Label, Phase 3, non-Inferiority Trial. Lancet Oncol (2019) 20(11):1531–43. doi: 10.1016/S1470-2045(19)30569-8 - DOI - PMC - PubMed
    1. Michalski JM, Gay H, Jackson A, Tucker SL, Deasy JO. Radiation Dose-Volume Effects in Radiation-Induced Rectal Injury. Int J Radiat Oncol Biol Phys (2010) 76:S123–9. doi: 10.1016/j.ijrobp.2009.03.078 - DOI - PMC - PubMed